CL2013002731A1 - Genoteca de ligando aleatorio para la selección de un fluido biológico complejo. - Google Patents

Genoteca de ligando aleatorio para la selección de un fluido biológico complejo.

Info

Publication number
CL2013002731A1
CL2013002731A1 CL2013002731A CL2013002731A CL2013002731A1 CL 2013002731 A1 CL2013002731 A1 CL 2013002731A1 CL 2013002731 A CL2013002731 A CL 2013002731A CL 2013002731 A CL2013002731 A CL 2013002731A CL 2013002731 A1 CL2013002731 A1 CL 2013002731A1
Authority
CL
Chile
Prior art keywords
selection
biological fluid
complex biological
ligand library
random ligand
Prior art date
Application number
CL2013002731A
Other languages
English (en)
Inventor
Muralidhar Reddy Moola
Jessica Schilke
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of CL2013002731A1 publication Critical patent/CL2013002731A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/08—Direct analysis of the library members per se by physical methods, e.g. spectroscopy
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/12—Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

UNA GANOTECA DE LIGARDO ALEATORIO PARA LA SELECCIÓN DE UN FLUIDO BIOLOGICO COMPLEJO QUE COMPRENDE UN COMPUESTO DE FORMULA 1 EN UN SOPORTE.
CL2013002731A 2011-03-24 2013-09-24 Genoteca de ligando aleatorio para la selección de un fluido biológico complejo. CL2013002731A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467256P 2011-03-24 2011-03-24
US201161491717P 2011-05-31 2011-05-31
US201261583881P 2012-01-06 2012-01-06

Publications (1)

Publication Number Publication Date
CL2013002731A1 true CL2013002731A1 (es) 2014-04-04

Family

ID=46880042

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002732A CL2013002732A1 (es) 2011-03-24 2013-09-24 Metodos de diagnostico utilizando una genoteca de ligandos.
CL2013002731A CL2013002731A1 (es) 2011-03-24 2013-09-24 Genoteca de ligando aleatorio para la selección de un fluido biológico complejo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013002732A CL2013002732A1 (es) 2011-03-24 2013-09-24 Metodos de diagnostico utilizando una genoteca de ligandos.

Country Status (13)

Country Link
US (2) US9804168B2 (es)
EP (2) EP2688911B1 (es)
JP (2) JP6153921B2 (es)
KR (2) KR20140027174A (es)
CN (2) CN103748270B (es)
AU (2) AU2012230880B2 (es)
BR (2) BR112013024453A2 (es)
CL (2) CL2013002732A1 (es)
CO (2) CO6870002A2 (es)
EA (2) EA032582B1 (es)
MX (2) MX2013011000A (es)
TW (2) TW201300591A (es)
WO (2) WO2012129423A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101694336B1 (ko) * 2012-08-03 2017-01-09 티엔진 폴리테크닉 유니버시티 리튬 동위원소 분리 효과를 나타내는 벤조크라운 에테르 그래프트 폴리머 및 그 제조 방법
WO2015169973A2 (de) * 2014-05-09 2015-11-12 Protagen Ag Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten
US10849875B2 (en) 2015-07-23 2020-12-01 University Of Houston System Cancer specific lipid targeted peptidomimetics
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
EP3426672B1 (en) 2016-03-09 2021-09-01 Mike-Ann, LLC Peptoid affinity ligands
US10458995B2 (en) 2016-03-25 2019-10-29 Muralidhar Reddy Moola Combinatorial synthesis and biomarker development
CN106854233B (zh) * 2017-03-03 2020-07-17 国家纳米科学中心 一种类肽及其制备方法和应用
US20240352068A1 (en) * 2021-08-04 2024-10-24 University Of Houston System Vimentin targeted peptoids for early diagnosis and treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US20040241759A1 (en) 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
EP1105360B1 (en) * 1998-08-17 2009-07-29 Bristol-Myers Squibb Company Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
WO2001039799A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Passive desensitization
US7153682B2 (en) 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
TW573125B (en) 2001-08-29 2004-01-21 Combinatorx Inc A screening system for identifying drug-drug interactions and methods of use thereof
US20060275829A1 (en) 2002-04-15 2006-12-07 Hammond David J Combinatorial library for proteomic investigations
US20060275753A1 (en) 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
AU2003299518A1 (en) * 2002-05-17 2004-05-13 Slanetz, Alfred E. Process for determining target function and identifying drug leads
CA2491969A1 (en) 2002-07-11 2004-01-22 The American National Red Cross Method for identifying individual active entities from complex mixtures
JP5072901B2 (ja) * 2003-02-24 2012-11-14 譲治 稲澤 薬剤耐性マーカーおよびその利用
WO2004080957A2 (en) * 2003-03-12 2004-09-23 Ramot At Tel Aviv University Ltd. Use of adnf polypeptides for treating anxiety and depression
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
CN1809383A (zh) * 2003-04-11 2006-07-26 免疫医疗公司 重组il－9抗体及其用途
US20060121489A1 (en) * 2003-05-23 2006-06-08 Board Of Regents, The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
EP1644536A4 (en) * 2003-07-08 2008-07-23 Univ California GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF
WO2005045430A1 (en) * 2003-10-08 2005-05-19 The Regents Of The University Of California Screening combinatorial bead libraries for cancer ligands
JP2006025069A (ja) * 2004-07-07 2006-01-26 Hitachi Ltd 機器制御装置及び電気機器
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US20060199206A1 (en) * 2005-03-01 2006-09-07 Hong Wang Method for identifying skin care composition-resistant skin-binding peptides
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8119572B2 (en) 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
US20070111322A1 (en) * 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
WO2007137405A1 (en) * 2006-05-25 2007-12-06 University Health Network Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20100266610A1 (en) * 2007-05-03 2010-10-21 Medimmune, Llc Auto-antibody markers of autoimmune disease
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
TWM333876U (en) 2007-09-21 2008-06-11 Jer-Yuan Jang Device of auxiliary bathing tool
GB0724735D0 (en) * 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2010014651A1 (en) * 2008-07-31 2010-02-04 The Brigham And Women's Hospital, Inc. Pharmacogenetic markers for susceptibility to drug-induced pancreatic toxicity
JP2010071744A (ja) * 2008-09-17 2010-04-02 Sekisui Chem Co Ltd 化合物のスクリーニング方法、並びに、スクリーニング用キット
WO2010138797A1 (en) 2009-05-29 2010-12-02 The Board Of Regents Of The University Of Texas System Peptoid ligands for isolation and treatment of autoimmune t-cells
BRPI1013012A2 (pt) * 2009-06-02 2016-10-18 Opko Health Inc identificação de pequenas moléculas reconhecidas por anticorpos em indivíduos com doenças neurodegenerativas
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
EP2486404B1 (en) * 2009-10-06 2018-08-15 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
WO2011047257A1 (en) * 2009-10-16 2011-04-21 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries

Also Published As

Publication number Publication date
EP2689053B1 (en) 2018-11-14
EP2688911A2 (en) 2014-01-29
CN103748270B (zh) 2018-04-24
JP2014510919A (ja) 2014-05-01
TW201310033A (zh) 2013-03-01
EA201391378A1 (ru) 2014-09-30
EP2688911A4 (en) 2015-08-26
MX2013010999A (es) 2014-03-27
EA201391382A1 (ru) 2014-09-30
KR20140027174A (ko) 2014-03-06
CL2013002732A1 (es) 2014-04-04
KR20140029411A (ko) 2014-03-10
EP2689053A2 (en) 2014-01-29
AU2012230880B2 (en) 2017-04-13
US20120269799A1 (en) 2012-10-25
HK1197088A1 (en) 2015-01-02
JP6153921B2 (ja) 2017-06-28
AU2012230818B2 (en) 2016-12-08
EA032582B1 (ru) 2019-06-28
CN103562444A (zh) 2014-02-05
WO2012129457A2 (en) 2012-09-27
BR112013024453A2 (pt) 2016-09-06
MX351228B (es) 2017-09-06
AU2012230818A1 (en) 2013-10-24
TW201300591A (zh) 2013-01-01
WO2012129457A3 (en) 2013-12-12
US20120270741A1 (en) 2012-10-25
WO2012129423A2 (en) 2012-09-27
JP6412798B2 (ja) 2018-10-24
CN103748270A (zh) 2014-04-23
CO6870029A2 (es) 2014-02-20
JP2014515739A (ja) 2014-07-03
EP2689053A4 (en) 2015-05-06
US9804168B2 (en) 2017-10-31
TWI630389B (zh) 2018-07-21
AU2012230880A1 (en) 2013-10-24
CN103562444B (zh) 2017-08-25
WO2012129423A3 (en) 2012-11-22
MX2013011000A (es) 2014-03-27
EP2688911B1 (en) 2017-08-02
BR112013024454A2 (pt) 2017-09-19
CO6870002A2 (es) 2014-02-20
EA037648B1 (ru) 2021-04-27

Similar Documents

Publication Publication Date Title
CL2013002731A1 (es) Genoteca de ligando aleatorio para la selección de un fluido biológico complejo.
CR20130661A (es) Inhibidores de activacion de las celulas t
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
UY34330A (es) ??COMPOSICIONES Y MÉTODOS PARA CONTROLAR MALEZAS COMPRENDIENDO UN POLINUCLEÓTIDO Y AGENTE DE TRANSFERENCIA, Y QUE MODULAN LA ACETIL-CoA CARBOXILASA?
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UY4230Q (es) Bocadillo retorcido para mascota
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CR20130539A (es) Triazolopiridinas
UY34013A (es) ?compuestos de cromenona con actividad anti-tumoral?.
BR112014009385A2 (pt) válvula óleo hidráulica
EP2972817A4 (en) PROCESS FOR EXPLORING ILLUSTRATIONS OF SOURCE CODES
UY34537A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
BR112014001219A2 (pt) perfume
UY34666A (es) Inhibidores de quinasa a base de ariléter
BR112014017556A8 (pt) lubrificante de poliéster para fluidos de trabalho que compreendem difluorometano
UY34222A (es) Partículas que comprenden un principio activo a base de poliacrilato
UY34142A (es) Composiciones que contienen sal de colina para limpieza
DK3060638T3 (da) Fedtaminsalte som friktionsmodifikatorer til smøremidler
BR112013025018A2 (pt) esp com mancais carregados lateralmente compensados
AR105967A1 (es) Sales de un inhibidor de pim quinasa
CL2014003495A1 (es) Agentes herbicidas que contienen flufenacet.
EP2756433A4 (en) EFFICIENT PROVISION OF MULTIPLE METADATA DISPLAYS OF THE SAME TYPE
BR112013029018A2 (pt) folga ajustável para um rolamento fluido dinâmico